342 related articles for article (PubMed ID: 38254927)
1. Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.
Izhar R; Borriello M; La Russa A; Di Paola R; De A; Capasso G; Ingrosso D; Perna AF; Simeoni M
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254927
[TBL] [Abstract][Full Text] [Related]
2. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation impact on Fabry disease.
Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls of X-chromosome inactivation testing in females with Fabry disease.
Řeboun M; Sikora J; Magner M; Wiederlechnerová H; Černá A; Poupětová H; Štorkánova G; Mušálková D; Dostálová G; Goláň L; Linhart A; Dvořáková L
Am J Med Genet A; 2022 Jul; 188(7):1979-1989. PubMed ID: 35338595
[TBL] [Abstract][Full Text] [Related]
5. X-chromosomal inactivation patterns in women with Fabry disease.
Wagenhäuser L; Rickert V; Sommer C; Wanner C; Nordbeck P; Rost S; Üçeyler N
Mol Genet Genomic Med; 2022 Sep; 10(9):e2029. PubMed ID: 35971858
[TBL] [Abstract][Full Text] [Related]
6. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
7. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
9. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
[TBL] [Abstract][Full Text] [Related]
11. Female Fabry disease patients and X-chromosome inactivation.
Juchniewicz P; Kloska A; Tylki-Szymańska A; Jakóbkiewicz-Banecka J; Węgrzyn G; Moskot M; Gabig-Cimińska M; Piotrowska E
Gene; 2018 Jan; 641():259-264. PubMed ID: 29079200
[TBL] [Abstract][Full Text] [Related]
12. The heart in Fabry's disease.
Sheppard MN
Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
[TBL] [Abstract][Full Text] [Related]
13. X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay.
Rossanti R; Nozu K; Fukunaga A; Nagano C; Horinouchi T; Yamamura T; Sakakibara N; Minamikawa S; Ishiko S; Aoto Y; Okada E; Ninchoji T; Kato N; Maruyama S; Kono K; Nishi S; Iijima K; Fujii H
Clin Exp Nephrol; 2021 Nov; 25(11):1224-1230. PubMed ID: 34128148
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Molecular Mechanisms in Fabry Disease.
Amodio F; Caiazza M; Monda E; Rubino M; Capodicasa L; Chiosi F; Simonelli V; Dongiglio F; Fimiani F; Pepe N; Chimenti C; Calabrò P; Limongelli G
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291669
[TBL] [Abstract][Full Text] [Related]
15. X-chromosome inactivation in female patients with Fabry disease.
Echevarria L; Benistan K; Toussaint A; Dubourg O; Hagege AA; Eladari D; Jabbour F; Beldjord C; De Mazancourt P; Germain DP
Clin Genet; 2016 Jan; 89(1):44-54. PubMed ID: 25974833
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
17. Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report.
Rodríguez Doyágüez P; Furlano M; Ars Criach E; Arce Y; Guirado L; Torra Balcells R
Nefrologia (Engl Ed); 2023 Dec; 43 Suppl 2():91-95. PubMed ID: 38278716
[TBL] [Abstract][Full Text] [Related]
18. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
19. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the
Hossain MA; Wu C; Yanagisawa H; Miyajima T; Akiyama K; Eto Y
Mol Genet Metab Rep; 2019 Sep; 20():100497. PubMed ID: 31372342
[TBL] [Abstract][Full Text] [Related]
20. Fabry Disease: The Current Treatment Landscape.
Lenders M; Brand E
Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]